Utility of GPIIb/IIIa inhibitor in patients with medium-low clinical risk but with high risk of periprocedural necrosis in coronary lesion.

Trial Profile

Utility of GPIIb/IIIa inhibitor in patients with medium-low clinical risk but with high risk of periprocedural necrosis in coronary lesion.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 31 Oct 2011

At a glance

  • Drugs Eptifibatide (Primary) ; Heparin
  • Indications Angina pectoris; Coronary artery restenosis; Embolism and thrombosis
  • Focus Therapeutic Use
  • Acronyms GPIAP
  • Most Recent Events

    • 08 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top